Complementing the net benefit approach: A new framework for Bayesian cost-effectiveness analysis

International Journal of Technology Assessment in Health Care

Volumn 25, Issue 4, 2009, Pages 537-545

  Hernández, Miguel Angel Negrín ^a   Vázquez Polo, Francisco José ^a   Gonzélez Torre, Francisco Javier Girón ^b   Bas, Elías Moreno ^c  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b UNIVERSITY OF MÁLAGA   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Bayesian analysis; Binary effectiveness; Cost effectiveness; Net benefit; Predictive posterior densities

Indexed keywords

BAYESIAN; BAYESIAN ANALYSIS; CATEGORICAL VARIABLES; COST EFFECTIVENESS ANALYSIS; DECISION MAKERS; DEGREE OF ASYMMETRY; HEALTH BENEFITS; INCREMENTAL COST; POSTERIOR DISTRIBUTIONS; UNDERLYING DISTRIBUTION;

BAYESIAN NETWORKS; COST EFFECTIVENESS; COSTS; DECISION MAKING;

COST BENEFIT ANALYSIS;

ARTICLE; BAYES THEOREM; CLINICAL DECISION MAKING; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE COST; OUTCOME ASSESSMENT; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; QUALITY ADJUSTED LIFE YEAR; UNCERTAINTY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BAYES THEOREM; COST-BENEFIT ANALYSIS; DECISION MAKING; HIV INFECTIONS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNCERTAINTY;

EID: 74049119487     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990444     Document Type: Article

References (25)

1. Al MJ, van Hout BA. A Bayesian approach to economic analyses of clinical trials: The case of Stenting versus Balloon Angioplasty. Health Econ. 2000;9:599-609.
2. Briggs AH. A Bayesian approach to stochastic costeffectiveness analysis. Health Econ. 1999;8:257-261.
3. Brock DW. Ethical issues in the use of cost-effectiveness analysis for the priorization of health resources. In: Khushf G, ed. Handbook of bioethics: Taking stock of the field from a philosophical perspective. Emeryville, CA: Springer-Verlag Telos; 2004.
4. Carpenter C, Fischl M, Hammer S, et al. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78-86.
5. Elbasha E. Risk aversion and uncertainty in cost-effectiveness analysis: The expected utility, moment-generating function approach. Health Econ. 2005;14:457-470.
6. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-787.
7. Gold MR, Siegel JE, Russell LB, Weinstein MC. Costeffectiveness in health and medicine.Oxford: Oxford University Press; 1996.
8. Heitjan DF, Moskowitz AJ, William W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ. 1999;8:191-201.
9. Hoch JS, Rockx MA, Krahn A. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: An example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Serv Res. 2006;6: 68.
10. Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ. 2000;9:623-630.
11. Michiels S, Piedbois P, Burdett S, et al. Meta-analysis when only the median survival times are known: A comparison with individual patient data results. Int J Technol Assess Health Care. 2005;21:119-125.
12. O'Brien BJ, Sculpher MJ. Building uncertainty into costeffectiveness rankings: Portfolio risk-return tradeoffs and implications for decision rules. Med Care. 2001;38:460-468.
13. O'Hagan A. Research in elicitation. In: Upadhyay SK, Singh U, Dey DK, eds. Bayesian statistics and its applications. New Delhi: Anamaya; 2006:375-382.
14. O'Hagan A, Forster J. Kendall's Advanced theory of statistics. vol.2B. Bayesian inference. 2nd ed. London: Edward Arnold; 2004.
15. O'Hagan A, Stevens JW. Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies. Stat Methods Med Res. 2002;11:469-490.
16. O'Hagan A, Stevens JW. The probability of cost-effectiveness. BMC Med Res Methodol. 2002;2:5.
17. O'Hagan A, Stevens JW, Montmartin J. Bayesian costeffectiveness analysis from clinical trial data. Stat Med. 2001;20:733-753. (Pubitemid 32177846)
18. Pinto JL, Ĺopez C, Bad̀ia X, Coma A, et al. Ańalisis costeefectividad del tratamiento antirretroviral de gran actividad en pacientes infectados por el VIH asintoḿaticos. Med Clin. 2000;114:62-67.
19. Polsky D, GlickH,Willke R, SchulmanK. Confidence intervals for cost-effectiveness ratios: A comparison of four methods. Health Econ. 1997;6:243-252.
20. Spiegelhalter DJ, Thomas A, Best NG, Lunn D. Winbugs version 1.4 user manual. T. Rep., MRC Biostatistics Unit, 2002. http://www.mrc-bsu.cam.ac.uk/bugs (accessed September 2, 2009).
21. Stinnett AA, Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1993;18:S68-S80.
22. Vanness DJ,Mullahy J. Perspectives on mean-based evaluation of health care. In: Jones AM, ed. Elgar companion to health economics. Cheltenham: Edward Elgar Publishing; 2006:526-536.
23. Wailoo A, Roberts J, Brazier J, McCabe C. Efficiency, equity and NICE clinical guidelines. BMJ. 2004;328:536-537. (Pubitemid 38316620)
24. Willan AR. On the probability of cost-effectiveness using data from randomized clinical trials. BMC Med Res Methodol. 2001;1:8.
25. Zivin JG. Cost-effectiveness analysis with risk aversion. Health Econ. 2001;10:499-508.